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1 Drug description 
Generic/Brand name/ATC code: Lenalidomide/Revlimid®/ L04AX04 
Developer/Company: Celgene Europe Limited 
Description: Lenalidomide is a second generation immune-modulatory 
agent with several modes of action, inducing anti-neoplastic, anti-
angiogenic, pro-erythropoietic and immune-modulatory effects. These 
effects are exerted by inhibition of TNF-α production, activation of T-cells 
and by reduction of serum levels of the cytokines vascular endothelial 
growth factor and basic fibroblast growth factor [1, 2]. 
Revlimid® capsules are available at different dosages: 2.5 mg, 5 mg, 10 mg, 
15 mg and 25 mg. The currently licensed dosage for previously treated mul-
tiple myeloma (MM) patients is 25mg lenalidomide in addition to 40mg 
dexamethasone.  
Dose adjustments are indicated for patients with impaired renal function 
[3]. Side-effects associated with this drug are venous thromboembolism and 
special caution is required in femalepatients of childbearing age, because le-
nalidomide causes foetal harm at all doses [4]. Furthermore, a higher inci-
dence of second primary cancers (e.g. myelodysplastic syndrome) was ob-
served under lenalidomide therapy.  
2 Indication 
Lenalidomide is indicated for the first-line therapy of patients with MM 
who are not eligible for high-dose chemotherapy with bone marrow trans-
plant.  
3 Current regulatory status 
In Europe, lenalidomide is not yet licensed for first-line therapy, but has 
market authorisation  
 in combination with dexamethasone for the treatment of MM patients 
who have received at least one prior therapy in 2007.  
Orphan drug designation was assigned in 2003 [5].  
In the U.S., lenalidomide is an orphan drug and only available within the 
RevAssist® Programme, a risk evaluation and mitigation strategy. The Food 
and Drug Administration (FDA) granted market authorisation for Rev-
limid® for [4]: 
 patients with transfusion-dependent anaemia due to low- or interme-
diate-1-risk myelodysplastic syndrome associated with a del(5q) ab-
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normality with or without additional cytogenetic abnormalities in 
December 2005.  
 MM, in combination with dexamethasone, in patients who have re-
ceived at least one prior therapy in June 2006.  
4 Burden of disease 
 MM is an incurable malignant plasma cell disorder characterised by oste-
olytic bone lesions, renal disease and immunodeficiency and belongs to the 
type of B-cell lymphoma. MM accounts for about 10% of all haematological 
malignancies and is after non-Hodgkin’s lymphoma (NHL) the second most 
common hematologic malignancy [6, 7]. The incidence of MM is estimated 
to be 4-6 per 100,000 habitants with a median age of 70 years at time of di-
agnosis with men being more often affected than women. About 20% of pa-
tients are symptom-free at time of diagnosis [8, 9]. MM is often referred to 
as a disease of the elderly with only about 35% of MM patients being young-
er than 65 years [10, 11]. Raised erythrocyte sedimentation rate, plasma vis-
cosity, serum protein or globulin lead to incidental detection of MM. Clini-
cal features of MM present at time of diagnosis are bone disease, impaired 
renal function, anaemia, hypercalcaemia, recurrent or persistent bacterial 
infection and hyperviscosity [12]. 
If a diagnosis of MM is suspected, a range of investigations and tests are in-
dicated to confirm diagnosis, to estimate tumour burden and prognosis and 
to assess myeloma-related organ impairment. Further, these tests aim to dif-
ferentiate between patients with active and symptomatic MM that requires 
systemic therapy and monoclonal gammopathy of undetermined signifi-
cance (MGUS), smouldering or indolent myeloma or solitary plasmocytoma, 
all of which not requiring systemic therapy in the first instance [6, 8, 12].  
The natural history of MM is very heterogeneous. Initially, the Durie and 
Salmon system [13] was the staging system of choice until it was superseded 
by the International Staging System (ISS) for MM [14]. The ISS defines 3 
risk categories (stages I, II and III) with a corresponding median survival 
time of 62, 45 and 29 months in stages I, II and III, respectively. Especially 
biological parameters (e.g. β2-microglobulin, C-reactive protein, lactate de-
hydrogenase and serum albumin) are of prognostic relevance and thus in-
corporated in the determination of the ISS stages [8, 12]. Though, the ISS is 
valid for prognostic purposes, its use to determine choice of therapy for in-
dividual patients is still unproven [12]. Factors associated with poor progno-
sis are genetic abnormalities such as t(4;14), t(14;16) and deletion 17p dem-
onstrated by fluorescence in situ hybridisation (FISH) [12]. Patients pre-
senting these prognostic factors are generally referred to as “high-risk” MM 
patients. Preliminary data suggest that the adverse effects (AEs) of these fac-
tors may be abrogated by newer agents, but to confirm this observation fur-
ther prospective evaluation is required [12].  
According to clinical treatment guidelines only patients younger than 65 
years are eligible for ASCT. With an incidence of 4 per 100,000 habitants [8, 
9], there are about 360 patients newly diagnosed with MM in Austria per 
year. Applying the above mentioned estimates, nearly 200 patients older 
than 65 years are newly diagnosed with symptomatic disease each year. In 
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Europe, there are about 21,000 new MM cases and approximately 16,000 
deaths per year [15]. 
5 Current treatment 
Choice of therapy depends on the stage of disease and on presence or ab-
sence of symptoms. For MM of ISS stage I or indolent myeloma immediate 
treatment is not recommended [8].  
For patients with advanced stage (stage II or III) or symptomatic myeloma 
choice of first-line therapy depends on age, or at least on the overall condi-
tion of the MM patient. For younger patients (<65 years) or patients in good 
clinical condition the current standard of care is high-dose therapy (HDT) 
with melphalan and autologous stem-cell transplantation (ASCT). However, 
the age limit of 65 years is rather arbitrary since the decision whether MM 
patients are eligible for HDT with ASCT mainly depends on their overall 
performance status and co-morbidities (e.g. serious heart, lung, renal or liver 
dysfunction) [16, 17].  
 
For patients ineligible for transplant several agents are available and can be 
used either alone or in combination. These agents are: 
 Steroids (e.g. dexamethasone and prednisone). 
 Thalidomide. 
 Lenalidomide. 
 Bortezomib. 
 Alkylating agents (e.g., melphalan and cyclophosphamide). 
 Other cytotoxic drugs (e.g., vincristine, doxorubicin, and liposomal 
doxorubicin). 
No standard of care has been defined yet and enrolment onto clinical trials 
is therefore highly recommended. However, commonly used regimens in the 
first-line setting are:  
 MPT: melphalan, prednisolone, thalidomide 
 VMP: bortezomib, melphalan, and prednisone [9, 18-22].  
 
 
 
 
 
symptomatic MM: 
1st-line therapy is HDT 
with ASCT support in 
patients <65 years 
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6 Evidence 
A literature search was conducted in four databases (Ovid Medline, Embase, 
Cochrane Library, CRD Database) on 3rd of September 2012. Overall 626 
references were identified. Of these, one phase III trial [23] (including sup-
plementary material [24, 25]), one phase I/II study [26] and one retrospec-
tive analysis [27] were included in this report.  
6.1 Efficacy and safety - Phase III studies 
Table 1: Summary of efficacy 
Study title  
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma [23, 28] 
Study  
identifier 
ClinicalTrials.gov number:  NCT00405756, Protocol Number: CC-5013-MM-015 
Randomised (1:1:1 ratio), double-blind, multicentre (82 centres in Europe, Australia, Israel), placebo controlled, 3-
arm parallel group study, phase III  
Design 
Duration  Enrolment: February 2007 – September 2008 
Median follow-up: 30 months 
Cut-off date for final analysis: On-going (estimated study completion date: September 
2013) 
Hypothesis Superiority 
Funding Celgene 
Overall 459 patients 
Control (MP) 
(n=154) 
Induction: 28-day cycles of melphalan (0.18 mg/kg days 1 - 4), prednisone (2 mg/kg days 1 -
4) and placebo 
Maintenance: placebo 
Intervention 1 (MPR-
R) 
(n=152) 
Induction: 28-day cycles of melphalan (0.18 mg/kg days 1 - 4), prednisone (2 mg/kg days 1 -
4), and lenalidomide (10 mg days 1 - 21) 
Maintenance: lenalidomide (10 mg days 1 - 21 of each 28-day cycle) until disease progres-
sion or the development of unacceptable rates of adverse effects. 
Treatment 
groups 
Intervention 2 
(MPR) 
(n= 153) 
Induction: 28-day cycles of melphalan (0.18 mg/kg days 1 - 4), prednisone (2 mg/kg days 1 -
4), and lenalidomide (10 mg days 1 - 21) 
Maintenance: placebo 
Progression-free 
survival 
(primary outcome) 
PFS time of randomization until the date of progression (based on the myeloma re-
sponse criteria [29]) or death from any cause during treatment or until data censor-
ing at the last date at which the patient was known to be progression-free. 
Overall survival OS time of randomization until the date of death from any cause or until data censor-
ing at the last date at which the patient was known to be alive. 
Endpoints and 
definitions 
Response rate RR based on the myeloma response criteria [29]: categories of response will include 
complete response (CR), partial response (PR), stable disease (SD), and progressive 
disease (PD) [24] 
 
1 phase III, 1 phase I/II 
trial, 1 retrospective 
analysis 
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Time to response TTR calculated as the time from randomisation to the first documented objective re-
sponse including CR and PR [24] 
Duration of response DOR time from the initial response to the first documentation of confirmed progressive 
disease [24] 
Results and analysis 
Analysis  
description 
Intention-to-treat: to detect a 50% improvement in median progression-free survival, from 15 months (MP) to 
22.5 months (MPR-R). 
Characteristics 
Age, median (range) in 
yrs 
65 – 75/>75 in yrs (%) 
Sex: male/female (%) 
Karnofsky PS score, me-
dian (range) 
ISS: I/II/III (%) 
Control 
72 (65 - 91) 
 
75.3/24.7 
48.7/51.3 
90 (60 – 100) 
18.2/31.2/50.6 
Intervention 1 
71 (65 – 87) 
 
76.3/23.7 
46.7/53.3 
80 (60 – 100) 
18.4/32.9/48.7 
Intervention 2 
71 (65 – 86) 
 
75.8/24.2 
53.6/ 46.4 
80 (60 – 100) 
18.2/31.2/50.6 
Inclusion symptomatic, measurable, newly diagnosed multiple myeloma who were not candi-
dates for transplantation (≥65 years of age) were eligible for this trial 
Analysis  
population 
Exclusion absolute neutrophil count of less than 1500 per cubic millimetre, a platelet count of less 
than 75,000 per cubic millimetre, a haemoglobin level of less than 8.0 g per decilitre, 
renal insufficiency (a serum creatinine level of >2.5 mg per decilitre [>221 μmol per li-
tre]), and peripheral neuropathy of grade 2 or higher 
 Control (MP) Intervention 1 (MPR-R) Intervention 2 (MPR) 
Treatment group overall N = 154 N = 152 N = 153 
PFS, median (months) 13.0 31.0 14.0 
3-year OS, %  66 70 62 
RR (%) 
CR 
PR 
Very good PR 
SD 
PD 
Not evaluable 
50.0 
3.2 
46.8 
9.1 
45.5 
0 
4.5 
77.01  
9.9 
67.1 
23.01 
18.4 
0 
4.6 
68.02  
3.3 
64.7 
29.4 
26.1 
1.3 
4.6 
Descriptive sta-
tistics and esti-
mated  
 
 
 
 
 
 
 
 
TTR, median (months) 
Range 
3 
1 -15 
21 
1-9 
21 
1-6 
                                                             
1 P<0.001 for the comparison with the MP group 
2 P=0.002 for the comparison with the MP group 
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DOR (months) 
CR + PR, median 
(95%CI) 
CR, median (95%CI) 
PR, median (95%CI)  
 
13 (10 – 18) 
 
22 (10 -24) 
10 (9 – 15) 
 
29 (22 – NR)3 
 
NR (36 – NR)3  
19 (11 –NR) 
 
13 (12 – 15) 
  
31 (23 -33) 
11 (9 – 13) 
QoL NA NA NA 
Subgroup analyses    
Maintenance group N = 102 N = 88 N = 94 
PFS, median (months)  NR 26 7 
Patients 65 – 75 yrs N = 116 N = 116 N = 116 
PFS, median (months) 12 31 15 
Patients >75 yrs N = 38 N = 36 N = 37 
PFS, median (months) 15 19 12 
Comparison groups (overall study population) Intervention 1 (MPR-R)  vs Intervention 2 (MPR) 
HR 0.49 
95%CI NA 
P value  <0.001 
 Intervention 1 (MPR-R) vs Control (MP) 
HR 0.40 
95%CI NA 
PFS 
 
P value  <0.001 
 Intervention 1 (MPR-R)  vs Control (MP) 
HR 0.95 
95%CI NA 
P value  0.81 
 Intervention 1 (MPR - R) vs Intervention 2 (MPR) 
HR 0.79 
95%CI NA 
OS 
P value  0.25 
Comparison  groups (subgroup analyses) Intervention 1 (MPR-R) vs Intervention 2 (MPR) 
HR 0.34 
95%CI NA 
Effect estimate 
per comparison 
PFS (maintenance) 
P value  <0.001 
                                                             
3 P<0.001 for the comparison with th MPR group and the comparison with the MP group 
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 Intervention 1 (MPR-R) vs Intervention 2 (MPR) 
HR 0.48 
Variability NA 
P value  <0.001 
 Intervention 1 (MPR-R) vs  Control (MP) 
HR 0.30 
Variability NA 
PFS (age 65 – 70 yrs) 
Outcome 
P value  <0.001 
Notes Patients in whom progressive disease developed during induction therapy discontinued the double-blind treat-
ment phase and could enrol in an open-label extension phase to receive lenalidomide (25 mg on days 1 through 21 
of each 28-day cycle) alone or with dexamethasone (40 mg on days 1 through 4, 9 through 12, and 17 through 
20). All patients received aspirin thromboprophylaxis (75 to 100 mg daily) during induction. 
Three analyses were specified by the protocol, when 148 progression-free survival events (50%), 207 events 
(70%), and 296 events (100%) had occurred. On the basis of the first analysis (data cut-off, April 2009), the da-
ta and safety monitoring committee recommended unblinding of the study because the prespecified O’Brien–
Fleming superiority boundary (two-sided alpha level of 0.003 at 50% information [148 progression-free survival 
events]) for the primary end point had been crossed (hazard ratio, 0.50; P<0.001). 
 
Abbreviations: CR = complete response, CI = confidence interval, HR = hazard ratio, NA = not available; NR = not reached, PD = 
progressive disease, PR = partial response, SD =stable disease, QoL = quality of life, yrs = years,  
 
 
Table 2: most frequent adverse events of grade 3 and 4 (occurring in at least 5% of the safety population and adverse events of clinical 
interest occurring in at least 2% of the safety population) 
Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma [23, 28] 
Outcome, n (%) Control (MP) 
(n=153) 
Intervention 1 
(MPR-R) 
(n=150) 
Intervention 2 
(MPR) 
(n=152) 
Control (MP) 
(n=102) 
Intervention 1 
(MPR-R) 
(n=88) 
Intervention 
2 (MPR) 
(n=94) 
Grade (accord-
ing to CTC ver-
sion 3.0) 
Induction Maintenance 
Haematologic 
Neutropenia 45 (29) 100 (67) 97 (64) 1 (1) 4 (5) 0 
Thrombocytopenia 18 (12) 53 (35) 58 (38) 2 (2) 0 0 
Anaemia 21 (14) 36 (24) 40 (26) 5 (5) 2 (2) 2 (2) 
Leukopenia  21 (14) 35 (23) 39 (26) - - - 
Febrile neutropenia 0 7 (5) 2 (1) - - - 
Non-haematologic 
Infection  11 (7) 14 (9) 20 (13) 1 (1) 3 (3) 2 (2) 
Fatigue  5 (3) 8 (5) 2 (1) 1 (1) 2 (2) 0 
Deep-vein throm-
bosis 
1 (1) 2 (1) 6 (4) 0 2 (2) 1 (1) 
Cardiac disorder 5 (3) 5 (3) 4 (3) - - - 
Diarrhoea  0 3 (2) 2 (1) 0 3 (3) 0 
Rash 2 (1) 7 (5) 7 (5) - - - 
Bone pain - - - 4(4) 4(5) 1 (1) 
Grade 3 
Diabetes mellitus - - - 0 2 (2) 0 
Horizon Scanning in Oncology 
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Haematologic 
Neutropenia 12 (8) 52 (35) 49 (32) 0 2 (2) 0 
Thrombocytopenia 6 (4) 17 (11) 19 (12) 0 5 (6) 2 (2) 
Anaemia 2 (1) 4 (3) 4 (3) 0 2 (2) 1 (1) 
Leukopenia  2 (1) 6 (4) 8 (5) - - - 
Febrile neutropenia 0 3 (2) 2 (1) - - - 
Non-haematologic 
Infection  0 1 (1) 3 (2) 2 (2) 2 (2) 0 
Fatigue  0 0 1 (1) 0 1 (1) 0 
Deep-vein throm-
bosis 
0 0 1 (1) 0 0 0 
Cardiac disorder 0 3 (2) 4 (3) - - - 
Diarrhoea  0 1 (1) 0 0 1 (1) 0 
Rash 0 0 0 - - - 
Bone pain - - - 1 (1) 0 0 
Grade 4 
Diabetes mellitus - - - 0 0 0 
Treatment-related 
deaths 
- 3 (2) 1 (1) - - - Others  
Discontinuation 
due to AE [28] 
8 (5) 24 (16) 22 (14) - 8 (9) - 
 
This phase III trial evaluated lenalidomide induction and maintenance 
therapy in patients aged ≥65 years who were considered ineligible for high-
dose chemotherapy and ASCT. 459 patients were randomised in a 1:1:1 ratio 
to either of three groups: 1. melphalan + prednisone + placebo induction 
therapy followed by placebo maintenance (MP), 2. melphalan + prednisone 
+ lenalidomide induction followed by lenalidomide maintenance therapy 
(MPR–R) or to 3. melphalan + prednisone + lenalidomide induction fol-
lowed by placebo maintenance therapy (MPR). Patients who completed all 9 
cycles of induction therapy could enter maintenance therapy as well could 
patients who had to stop induction therapy due to intolerance. Patients with 
disease progression during induction therapy were unblinded and could en-
ter an open-label extension phase with either lenalidomide alone or in com-
bination with dexamethasone. Patients’ baseline characteristics were compa-
rable, with the exception of a better Karnofsky performance status score in 
the MP group than in the two other groups. Median age was 71 years.  
The primary outcome was progression-free survival (PFS) in the MPR-R 
group compared to the MP group. Overall, median PFS was 31 months in 
the MPR-R group, 14 months in the MPR and 13 months in the MP group.  
Risk of progression or death was reduced by 60% in the MPR-R group in 
comparison to the MP group and by 51% in comparison to the MPR group. 
Between the two groups without lenalidomide maintenance therapy (i.e. 
MPR and MP) no difference in PFS existed. An additional analysis com-
pared PFS from the start of maintenance therapy between the two groups 
which had been treated with lenalidomide induction therapy yielding a haz-
ard ratio of 0.34 (p<0.001). Furthermore, complete or partial responses, 
were superior for the two groups which had received lenalidomide and dura-
tion of response was significantly longer for the maintenance lenalidomide 
group (MPR-R) than for those with placebo maintenance (MPR + MP). 
phase III trial included 
459 patients randomised 
to three treatment arms 
lenalidomide induction 
therapy and 
lenalidomide 
maintenance therapy 
were compared to 
placebo 
PFS + 18 months in 
patients receiving 
lenalidomide induction 
and maintenance 
therapy vs placebo 
therapy 
this gain mainly due to 
maintenance therapy  
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Thus the main effect on PFS was triggered by maintenance therapy with le-
nalidomide. However, patients entering the maintenance phase (overall 284 
patients that is 62%) had a higher proportion of patients ≤75 years, scored 
better on the ISS and had a better renal function than those initially ran-
domised [28].  
PFS subgroup analyses (according to gender, ISS, renal function or β2-
microglobulin and albumin levels, Karnofsky PS) comparing MPR-R and 
MP always favoured the lenalidomide group. Only in the rather small group 
of patients aged >75 years no significant difference existed [28]. 3-year OS 
rates were comparable between the three groups but these outcomes might 
be confounded due to crossing-over to lenalidomide and 46% received sec-
ond-line therapy in the MPR-R group, 69% in the MPR and 76% in the MP 
group respectively [28].  
Higher grade haematologic AEs during induction therapy occurred more of-
ten in the lenalidomide groups than in the placebo group (see table 2) and 
more patients in these groups received granulocyte colony-stimulating factor 
and platelet transfusion.  Also, a higher proportion of patients in the MPR-R 
and in the MPR group discontinued therapy due to AEs. 2% of deaths in the 
MPR-R group and 1% in the MPR group, respectively, were considered as 
treatment-related; no results were provided for the MP group. Second pri-
mary tumours developed in 7% of patients in the two lenalidomide groups 
in contrast to 3% in the MP group. Only haematologic second primary tu-
mours were mentioned in the publication and included acute myeloid leu-
kaemia (4 patients in the MPR-R, 2 in the MPR group), myelodysplastic 
syndromes (1 patient in the MPR-R group, 3 in the MPR group), T-cell 
acute lymphoblastic leukaemia (1 patient in the MPR-R group) and chronic 
myelomonocytic leukaemia (1 in the MPR-R group). Tumours other than 
hematologic ones were observed in 5 patients in the MPR-R group, in 4 in 
the MPR and in 3 in the MP group.  
In the maintenance phase side-effects were less frequent (see table 2).  
6.2 Efficacy and safety - further studies 
Prior to the phase III trial, the maximum tolerated MPR-R dose was elicited 
in a phase I/II dose-escalation study [30]. Results for patients who had been 
treated with this maximum dose (the regimen used in the phase III study) 
were presented in a separate publication [26]. 21 transplant ineligible pa-
tients with a median age of 69 years were enrolled. 19% discontinued ther-
apy due to AEs, 33% initially reduced therapy of which 19% stopped ther-
apy eventually. Grade 3 and 4 neutropenia was seen in 38% and in 14% of 
patients, and thrombocytopenia in 14% and 10%. Non-haematologic AEs of 
grade 3/4 occurred in 29%, with the most frequent ones being febrile neu-
tropenia (10%) and vasculitis (10%). Thromboembolic events were seen in 
5%. For efficacy outcomes, a median PFS of 28.5 months, complete re-
sponses in 24% and partial responses in 33% were reported. OS at 2 years 
was 91%.  
no significant difference 
for patients >75 years  
but all other subgroup 
analyses favoured 
lenalidomide therapy  
OS showed no 
difference 
patients entering 
maintenance therapy 
had better baseline 
characteristics than 
those initially enrolled 
AEs also more common 
in lenalidomide groups 
secondary primary 
tumours in 7% in 
lenalidomide treated 
patients and in 3% in 
placebo group 
1 phase I/II trial 
grade 3 neutropenia in 
38%, thromboembolic 
events in 5% 
PFS 28.5 months 
Horizon Scanning in Oncology 
12 LBI-HTA | 2012 
A retrospective analysis of 17 previously untreated patients treated with sin-
gle-agent lenalidomide was performed [27]. Patients received 25mg daily in-
stead of 10mg like in the phase III trial. The overall response rate was 47% 
and median time to first response was 50 days. Six patients needed dexa-
methasone due to disease progression. No grade 4 AEs were noted but 
thrombocytopenia, the most frequent AE of grade 3, was observed in 19%. 
No thromboembolic occurred.  
7 Estimated costs 
In Austria, the estimated costs for one package Revlimid® containing 21 cap-
sules of 10mg is 5,475.-€ [31], corresponding to the monthly costs of le-
nalidomide therapy. Overall treatment costs cannot be calculated, because 
the mean treatment duration is unknown.  
Besides costs for lenalidomide itself, expenditures for melphalan and pred-
nisone, as well as supportive treatment (e.g. granulocyte colony stimulating 
factor, platelet transfusion) have to be taken into account.   
8 Ongoing research 
On www.clinicaltrials.gov 5phase III trials for the first-line therapy of MM 
patients were found.  
 NCT01093196:  to compare three all-oral combinations: lenalido-
mide with dexamethasone in comparison with lenalidomide in as-
sociation with MP (MPR) and lenalidomide in association with cy-
clophosphamide - prednisone (in newly diagnosed symptomatic 
MM patients. Estimated study completion date: November 2014. 
 NCT00689936: to compare lenalidomide plus low-dose dexa-
methasone  until progressive disease or for 18 four-week cycles ver-
sus the combination of melphalan, prednisone, and thalidomide 
given for 12 six-week cycles in patients with previously untreated 
MM who are either 65 Years of age or older or not candidates for 
stem cell transplantation. Estimated study completion date: March 
2016. 
 NCT01554852: compares a standard chemotherapy regimen of cy-
clophosphamide, dexamethasone plus thalidomide with a newer 
regimen of cyclophosphamide, dexamethasone plus lenalidomide. 
Estimated primary completion date: September 2017.  
 NCT00551928: compares the combination of lenalidomide with 
low-dose melphalan versus high-dose melphalan in newly diag-
nosed, symptomatic MM patients. The stated study completion 
date was August 2011, but the protocol has not been updated re-
cently.  
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monthly treatment 
costs of € 5,400 
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 NCT01335399: compares the addition of elotuzumab to lenalido-
mide/low-dose dexamethasone. Estimated primary completion 
date: May 2016. 
On www.clinicaltrialsregister.eu 6 phase III trials were found: 
 2008-003486-58: A pharmacogenomic study to predict survival, best 
response and toxicity in newly diagnosed MM patients who are ei-
ther 65 years of age or older treated with either a combination of 
melphalan-prednisone-thalidomide or lenalidomide-
dexamethasone. Estimated study completion date: not available.  
 2007-004007-34: Randomized phase III trial in elderly patients with 
previously untreated symptomatic MM comparing MP-
Thalidomide followed by thalidomide maintenance versus MP-
Lenalidomide followed by maintenance with lenalidomide. Esti-
mated study completion date: not available. 
 2010-019173-16: to evaluate two regimens of bortezomib based in-
duction therapy and lenalidomide consolidation followed by le-
nalidomide maintenance treatment. Estimated study completion 
date: not available. 
 2006-001865-41: Determine the efficacy and safety of lenalidomide 
(Revlimid) in combination with melphalan and prednisone versus 
placebo plus melphalan and prednisone in subjects with newly di-
agnosed multiple myeloma who are 65 years of age or older. Esti-
mated study completion date: not available. 
 2008-004083-39: lenalidomide and dexamethasone with or without 
intensification by high-dose melphalan in the treatment of multiple 
myeloma. Estimated study completion date: not available. 
 2007-004823-39: to compare the efficacy of lenalidomide plus low-
dose dexamethasone given until progressive disease to that of the 
combination of melphalan, prednisone, and thalidomide given for 
12 six-week cycles. Estimated study completion date: not available. 
In addition, lenalidomide is under investigation for ASCT eligible MM pa-
tients and is in phase III for other cancers such as myelodysplastic syn-
drome, large B-cell lymphoma, chronic lymphocytic leukaemia and mantle 
cell lymphomas.  
9 Commentary  
For many decades, MP was considered standard therapy for transplant-
ineligible MM patients. With the advent of novel agents, this treatment par-
adigm has changed and combinations of bortezomib or thalidomide with 
MP are commonly used regimens for the first-line therapy of these patients. 
Lenalidomide, a drug currently licensed in Europe only for previously treat-
ed MM patients, was also evaluated in the first-line setting for transplant in-
eligible patients. A phase III trial compared MP and MPR followed by pla-
cebo maintenance to MPR followed by lenalidomide maintenance therapy 
[23]. Enrolled were 459 patients aged over 65 years who were considered in-
lenalidomide currently 
not licensed in Europe 
for first-line MM 
therapy 
increase in PFS mainly 
due to maintenance 
therapy 
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eligible for transplant. PFS was prolonged by 17 months in the MPR-R in 
comparison to MPR and by 18 months in comparison to MP. Between the 
two groups with placebo maintenance no difference in PFS existed. Re-
sponse rates also yielded improved results for patients treated with le-
nalidomide. Data on 3-year OS, on the other hand, were comparable be-
tween the treatment groups but these findings might have been compro-
mised due to crossing over to lenalidomide. AEs were also more frequent in 
the lenalidomide groups than in the MP only group. The most common 
higher-grade AEs (i.e.≥grade 3) during induction therapy were haema-
tologic side-effects (MPR-R vs MPR vs MP) such as neutropenia (67% vs 
64% vs 29%), thrombocytopenia (35% vs 38% vs 12%) and anaemia (24% vs 
26% vs 14%) and more patients consequently discontinued lenalidomide 
therapy due to AEs than in the placebo group.   
The increase in PFS in the MPR-R group is mainly attributable to le-
nalidomide maintenance therapy but only 88 patients (=58%) in the MPR-
R and 94 patients (=61%) in the MPR group entered the maintenance 
phase. Also, side-effects were less frequently observed than during induction 
therapy.  Despite the fact that no commonly accepted criteria for determina-
tion of transplant eligibility exist - besides age, co-morbidities and the bio-
logical age are being considered - the primary inclusion criteria (i.e. ≥65 
years, Karnofsky performance score ≥60%, no serious medical condition) 
did not necessarily result in identification of transplant-ineligible patients 
in the first place. Moreover, subjects entering the maintenance phase 
showed even better characteristics [25]. Hence, it remains questionable if 
these patients are actually comparable to those who would be deemed ASCT 
ineligible in clinical practice. A subgroup analysis comprising patients older 
than 75 years and thus potentially ineligible for ASCT indicated no statisti-
cally significant difference in PFS for patients treated with MPR-R in com-
parison to MP. The incidence of AEs in this age group would have been of 
interest, but was not reported. Hence, if elderly patients with potentially 
more comorbidities can actually benefit from lendalidomide therapy needs 
to be explored further.  
Another issue is the lack of convincing data for OS, since the validity of PFS 
and response rates as surrogates has not been established unequivocally [32, 
33]. Furthermore, since transplant ineligible patients are usually elderly pa-
tients with co-morbidities, it is of utmost importance if improvements in re-
sponse and PFS will actually translate into improved quality-of-life [34]. 
Even though assessment of health-related quality-of-life was planned ac-
cording to the study protocol [24], no results for this outcome were reported 
but would be, in light of high rates of AE, helpful in determining the utility 
of lenalidomide.  
Another point concerns the comparator used in the phase III study, because 
MP only, without agents such as bortezomib or thalidomide, cannot be con-
sidered standard of care anymore [21]. The comparison of MP + thalido-
mide to MP + lenalidomide is being assessed in an on-going phase III study 
(end of recruitment is planned for 2013) [34]. In the absence of direct com-
parative data, different side-effect profiles might offer a means for selecting 
therapy. For example, peripheral neuropathies, an AE associated with tha-
lidomide, are less common with lenalidomide [35, 36] which might thus be 
preferred for patients with existing neurologic disorders [35]. On the other 
hand, thromboembolic events during lenalidomide therapy are of concern. 
In the phase III study 3% of patients experienced deep vein thrombosis de-
spite thromboprophylaxis. A pooled analysis of three trials reported that 8% 
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of all patients experienced deep vein thrombosis despite the fact that the 
majority of patients (i.e. 88%) had received anticoagulants [37]. However, 
this analysis was based on only 125 patients.  
Also the risk of second primary cancers is increased with lenalidomide ther-
apy. The FDA released a safety announcement in May 2012, notifying the 
public that patients with newly diagnosed multiple myeloma who had been 
treated with lenalidomide after ASCT had almost a three-fold increased risk 
of developing new types of cancer, especially acute myeloid leukaemia, 
myelodysplastic syndromes and B-cell lymphoma malignancies [38]. EMA’s 
Committee for Medicinal Products for Human Use also addressed this ques-
tion, but concluded that the benefits still outweighed the risk associated 
with lenalidomide – at least for the currently licensed indication (i.e. previ-
ously treated patients) [39]. 
Due to the development of new treatment strategies for the first-line therapy 
of MM patients, the importance of frontline therapy with ASCT is being 
challenged [40]. Even though the phase III trial included patients who were 
considered transplant ineligible, the main effect of MPR-R was due to main-
tenance therapy in relatively young patients. If similar effects without in-
creased toxicity can be observed in elderly and frail patients too, needs to be 
investigated further. The optimal dosage, the best combination – if at all – as 
well as the best sequence of therapies still needs to be determined [1, 41]. Se-
lection of the optimal treatment strategy might also be improved by further 
characteristics such as cytogenetics [33, 35, 42]. 
but: 
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